

Hair Loss and Balding in Women: Lilac Corp Reviews a Study and Recommends Nolopecia for Hair Growth in Women

Lilac Corp discusses a study on a new discovery that links the ANGPT2 gene and hair loss and recommends Nolopecia, a natural treatment for hair growth in women.

SARASOTA, FL, UNITED STATES, June 17, 2018 /EINPresswire.com/ -- Female pattern hair loss is a specific type of hair loss that is common in postmenopausal women. Menopause causes a change in a woman's hormones, leading to a decrease in estrogen. Estrogen supplementation has been shown to increase hair growth in postmenopausal women. However, estrogen supplementation has serious side effects. and scientists aren't sure how exactly it works to increase hair growth. To study the link between estrogen and balding in women, researchers removed the ovaries of female mice, causing the mice to go through menopause and have hair loss [1]. Then they measured the expression of different genes in these mice. The

All natural hair loss supplement sold by Lilac Corp

scientists noticed a decrease in the expression of a gene called ANGPT2, which is controlled by the estrogen hormone. The researchers then supplemented the mice with the protein expressed by the ANGPT2 gene. The results showed hair regrowth after only 24 days. Interestingly, higher doses of

"

There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause an increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding."

Lilac Corp

the protein resulted in more hair growth. The researchers concluded that the protein expressed by the ANGPT2 gene can reverse hair loss in postmenopausal mice.

For women who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. The new treatment targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth. There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin. For more information on these products, see lilaccorp.com, or search Google. The search will produce the clinical studies that tested the treatments and showed the safety and effectiveness of the treatments. See also references below.

About Lilac Corp:

Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-



Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world. What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Sources:

- [1] Endo, Y., Obayashi, Y., Ono, T., Serizawa, T., Murakoshi, M., & Ohyama, M. (2018). Reversal of the hair loss phenotype by modulating the estradiol-ANGPT2 axis in the mouse model of female pattern hair loss. Journal Of Dermatological Science. doi: 10.1016/j.jdermsci.2018.04.001
- [2] Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther. 2016 Aug 29;10:2713-22
- [3] Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.
- [4] Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 Mar 3; 11:575-583

John Evans Lilac Corp 585-250-9999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.